EDNRB and cancer: While the combination treatment of macitentan and EDNRB gene therapy do not impact cancer proliferation, this negative result does not discount the endothelin axis as an important target for future studies on oral cancer treatment, because metastasis, not proliferation, is the single most important predictor of survival in oral SCC patients2,17.